December 2025 in “PubMed” Upadacitinib and oral minoxidil improved Crohn's disease and hair regrowth in a patient.
1 citations
,
January 2024 in “Curēus” Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.
January 2026 in “Journal of Dermatology Research and Therapy” This case series examines the management of recalcitrant Alopecia Areata (AA) in five Black pediatric patients using a combination therapy approach. The treatment included topical janus kinase inhibitors (JAKi), oral fexofenadine, and vitamin D supplementation, with additional therapies like oral upadacitinib, platelet-rich plasma, red light therapy, and excimer UVB phototherapy in some cases. All patients experienced significant hair regrowth and reduced disease severity, achieving Alopecia Areata Investigator Global Assessment scores of ≤ 1, indicating minimal or no disease activity. The study supports the efficacy of JAK inhibitors for pediatric AA and suggests that combination therapy can effectively reduce disease progression and prevent relapse, with minimal adverse effects.
124 citations
,
October 2019 in “Frontiers in Immunology” Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.
March 2025 in “Meditsinskiy sovet = Medical Council” Dupilumab and oral JAK inhibitors are effective for treating alopecia areata with atopic diseases.